1211 related articles for article (PubMed ID: 15309512)
21. Irinotecan in metastatic colorectal cancer: dose intensification and combination with new agents, including biological response modifiers.
Ducreux M; Köhne CH; Schwartz GK; Vanhoefer U
Ann Oncol; 2003; 14 Suppl 2():ii17-23. PubMed ID: 12810453
[TBL] [Abstract][Full Text] [Related]
22. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer.
Hurwitz HI; Fehrenbacher L; Hainsworth JD; Heim W; Berlin J; Holmgren E; Hambleton J; Novotny WF; Kabbinavar F
J Clin Oncol; 2005 May; 23(15):3502-8. PubMed ID: 15908660
[TBL] [Abstract][Full Text] [Related]
23. Targeted therapies in metastatic colorectal cancer: a systematic review and assessment of currently available data.
Kirstein MM; Lange A; Prenzler A; Manns MP; Kubicka S; Vogel A
Oncologist; 2014 Nov; 19(11):1156-68. PubMed ID: 25326159
[TBL] [Abstract][Full Text] [Related]
24. Current status of second-line therapy for metastatic colorectal cancer.
Rothenberg ML
Clin Colorectal Cancer; 2004 Jun; 4 Suppl 1():S16-21. PubMed ID: 15212701
[TBL] [Abstract][Full Text] [Related]
25. Which drug combination for colorectal cancer?
Doggrell SA
Expert Opin Pharmacother; 2004 Dec; 5(12):2621-4. PubMed ID: 15571479
[TBL] [Abstract][Full Text] [Related]
26. Systemic treatment of advanced colorectal carcinoma.
van Laarhoven HW; Punt CJ
Eur J Gastroenterol Hepatol; 2004 Mar; 16(3):283-9. PubMed ID: 15195891
[TBL] [Abstract][Full Text] [Related]
27. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Hurwitz H; Fehrenbacher L; Novotny W; Cartwright T; Hainsworth J; Heim W; Berlin J; Baron A; Griffing S; Holmgren E; Ferrara N; Fyfe G; Rogers B; Ross R; Kabbinavar F
N Engl J Med; 2004 Jun; 350(23):2335-42. PubMed ID: 15175435
[TBL] [Abstract][Full Text] [Related]
28. Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma.
Folprecht G; Lutz MP; Schöffski P; Seufferlein T; Nolting A; Pollert P; Köhne CH
Ann Oncol; 2006 Mar; 17(3):450-6. PubMed ID: 16303861
[TBL] [Abstract][Full Text] [Related]
29. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.
Chung KY; Shia J; Kemeny NE; Shah M; Schwartz GK; Tse A; Hamilton A; Pan D; Schrag D; Schwartz L; Klimstra DS; Fridman D; Kelsen DP; Saltz LB
J Clin Oncol; 2005 Mar; 23(9):1803-10. PubMed ID: 15677699
[TBL] [Abstract][Full Text] [Related]
30. Evidence-based update of chemotherapy options for metastatic colorectal cancer.
Damjanovic D; Thompson P; Findlay MP
ANZ J Surg; 2004 Sep; 74(9):781-7. PubMed ID: 15379811
[TBL] [Abstract][Full Text] [Related]
31. Epidermal growth factor receptor as a target for chemotherapy.
Vallbohmer D; Lenz HJ
Clin Colorectal Cancer; 2005 Apr; 5 Suppl 1():S19-27. PubMed ID: 15871762
[TBL] [Abstract][Full Text] [Related]
32. Targeted therapies in the treatment of colorectal cancers.
Alekshun T; Garrett C
Cancer Control; 2005 Apr; 12(2):105-10. PubMed ID: 15855893
[TBL] [Abstract][Full Text] [Related]
33. [Treatment of metastatic liver carcinoma: chemotherapy and immunotherapy].
Omura K
Nihon Geka Gakkai Zasshi; 2003 Oct; 104(10):730-4. PubMed ID: 14579760
[TBL] [Abstract][Full Text] [Related]
34. Irinotecan in the treatment of colorectal cancer: clinical overview.
Vanhoefer U; Harstrick A; Achterrath W; Cao S; Seeber S; Rustum YM
J Clin Oncol; 2001 Mar; 19(5):1501-18. PubMed ID: 11230497
[TBL] [Abstract][Full Text] [Related]
35. [New therapy options in colorectal carcinoma].
Folprecht G; Köhne CH
Ther Umsch; 2004 Jun; 61(6):373-8. PubMed ID: 15253162
[TBL] [Abstract][Full Text] [Related]
36. New developments in systemic chemotherapy in advanced colorectal cancer.
Cats A
Scand J Gastroenterol Suppl; 2003; (239):78-86. PubMed ID: 14743888
[TBL] [Abstract][Full Text] [Related]
37. Chemotherapy for metastatic colorectal cancer.
Rosales J; Leong LA
J Natl Compr Canc Netw; 2005 Jul; 3(4):525-9. PubMed ID: 16038643
[TBL] [Abstract][Full Text] [Related]
38. Irinotecan-based regimens in the adjuvant therapy of colorectal cancer.
Douillard JY
Clin Colorectal Cancer; 2005 Apr; 5 Suppl 1():S34-7. PubMed ID: 15871764
[TBL] [Abstract][Full Text] [Related]
39. Bevacizumab in the treatment of colorectal cancer.
Mulcahy MF; Benson AB
Expert Opin Biol Ther; 2005 Jul; 5(7):997-1005. PubMed ID: 16018743
[TBL] [Abstract][Full Text] [Related]
40. Use of bevacizumab in metastatic colorectal cancer: report from the Mexican opinion and analysis forum on colorectal cancer treatment with bevacizumab (September 2009).
Zinser-Sierra JW; Rodríguez-Ramírez S; Villalobos-Valencia R; Ramírez-Márquez M
Drugs R D; 2011; 11(2):101-11. PubMed ID: 21679003
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
